MKI67 and breast carcinoma: The assessment of Ki67 routinely for all cases of breast cancer is not recommended in most population based studies and meta-analyses, but the most widely accepted recommendation is that a standard framework for the scoring of Ki67 expression must be done by pathologists communicating with the multidisciplinary team for the breast cancer patients [11,12].